We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3B
AUM Growth
-$85.7M
Cap. Flow
-$518M
Cap. Flow %
-17.24%
Top 10 Hldgs %
35.54%
Holding
152
New
30
Increased
26
Reduced
33
Closed
32

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$60.8M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$55.6M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$40.9M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$39.9M
5
DYAX
DYAX CORPORATION
DYAX
+$35.8M

Top Sells

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$446M
2
ABBV icon
AbbVie
ABBV
+$89.8M
3
ADVM
Adverum Biotechnologies
ADVM
+$85.8M
4
BLUE
bluebird bio
BLUE
+$47.9M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$27.7M

Sector Composition

Rank Sector Weight
1 Healthcare 70.77%
2 Financials 3.42%
3 Technology 0.52%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
51
PUT
Exelixis
EXEL
$14.2B
$15M 0.5%
4,000,000
– –
PTLA
52
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$15M 0.5%
329,837
-244,709
-43% -$9.84M
PCRX icon
53
Pacira BioSciences
PCRX
$1.01B
$15M 0.5%
+212,000
New +$16.7M
HUM icon
54
Humana
HUM
$47.9B
$14.4M 0.48%
75,500
-30,800
-29% -$5.72M
TRUP icon
55
Trupanion
TRUP
$1.16B
$14.1M 0.47%
1,715,211
-386,637
-18% -$3.17M
GEN
56
DELISTED
Genesis Healthcare, Inc.
GEN
$14M 0.47%
2,119,616
+687,248
+48% +$4.64M
AAC
57
DELISTED
AAC Holdings
AAC
$13.2M 0.44%
303,027
-143,301
-32% -$5.27M
MRTX
58
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.5M 0.42%
397,660
+364,748
+1,108% +$10.7M
TNXP icon
59
Tonix Pharmaceuticals
TNXP
$188M
– –
0
– –
AXGN icon
60
Axogen
AXGN
$2.1B
$11.7M 0.39%
3,726,439
-144,385
-4% -$466K
IMMU
61
DELISTED
Immunomedics Inc
IMMU
$10.2M 0.34%
2,505,872
-100
-0% -$409
JUNO
62
DELISTED
Juno Therapeutics, Inc.
JUNO
$9.77M 0.33%
183,149
– –
FOMX
63
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$9.73M 0.32%
948,934
+269,307
+40% +$2.98M
ATXS
64
DELISTED
Astria Therapeutics
ATXS
$9.01M 0.3%
+12,301
New +$9.3M
ADYX
65
DELISTED
Adynxx Inc
ADYX
$8.85M 0.29%
+27,985
New +$8.27M
DERM
66
DELISTED
Dermira, Inc.
DERM
$8.71M 0.29%
496,387
+264,920
+114% +$4.09M
PACB icon
67
Pacific Biosciences
PACB
$422M
$8.56M 0.29%
1,485,861
-1,562,449
-51% -$9.04M
ATYR
68
aTyr Pharma
ATYR
$49M
$8.55M 0.28%
+32,966
New +$10.2M
AMPH icon
69
Amphastar Pharmaceuticals
AMPH
$870M
$7.88M 0.26%
448,532
– –
STJ
70
DELISTED
St Jude Medical
STJ
$7.87M 0.26%
107,719
+57,349
+114% +$4.14M
OXFD
71
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$7.77M 0.26%
561,226
+38,976
+7% +$527K
GNCA
72
DELISTED
Genocea Biosciences, Inc.
GNCA
$7.75M 0.26%
70,532
-35,000
-33% -$3.25M
RIGL icon
73
Rigel Pharmaceuticals
RIGL
$734M
$7.7M 0.26%
239,786
– –
RLYP
74
DELISTED
RELYPSA INC COM
RLYP
$7.45M 0.25%
+225,000
New +$7.74M
ARCT icon
75
Arcturus Therapeutics
ARCT
$165M
$7.12M 0.24%
155,493
-46,394
-23% -$2.13M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2015 Portfolio in Review

As of Q2 2015, Deerfield Management held 152 positions worth $3B, down 2.8% from $3.09B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Deerfield Management withdrew a net $518M in Q2 2015, closing 32 positions and reducing 33 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $446M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 60% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Alpine Immune Sciences Inc worth $56.5M.

  • Deerfield Management's largest Q2 2015 buy was Alpine Immune Sciences Inc: 933,103 shares worth $56.5M.
  • Deerfield Management added most to Viatris in Q2 2015, an estimated $60.8M increase.
  • Deerfield Management's biggest Q2 2015 reduction was bluebird bio, cutting an estimated $47.9M.
  • Deerfield Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $446M.
  • Deerfield Management's ten largest holdings make up 36% of its $3B portfolio in Q2 2015.
  • Deerfield Management opened 30 new positions and closed 32 in Q2 2015.
  • Deerfield Management's portfolio value fell 2.8% quarter-over-quarter to $3B.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.